None of the prostate cancer and only one of the guidelines for ovarian cancer recommend the use of this type of imaging (instead relying mainly on prostate-specific antigen (PSA), or a combination of gynaecological exams and CA125 testing respectively). This evidence concerns the gene MUC16 and ovarian cancer.